Robert Jotte, MD
Hematology & Oncology · Lone Tree, CONPI 1669457032
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,799 of the $80,382 with a category attached, or 69.4%. 16 manufacturers reported payments, led by Genentech USA, Inc. at 57.2% of the total. Reporting peaked in 2019 at $60,093 and has fallen 93.6% since, to $3,874 in 2025.
Across 75 payments — averaging $1071.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$46K
- E.r. Squibb & Sons, L.L.C.$10K
- F. Hoffmann-la Roche AG$10K
- AstraZeneca$5K
- Mirati Therapeutics, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $5K from 10 others
Across 2,020 payments — averaging $4625.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$1.4M
- Amgen$1.3M
- E.r. Squibb & Sons, L.L.C.$1.1M
- Genentech, Inc.$908K
- AstraZeneca$889K
- Eli Lilly$608K
- plus $3.1M from 21 others
What the payments were for
- Consulting fees$19,26424%
- Speaking & faculty fees$55,79969%
- Travel & lodging$3,0674%
- Food & beverage$2,1963%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 29 | $45,954 |
| E.r. Squibb & Sons, L.L.C. | 7 | $9,985 |
| F. Hoffmann-la Roche AG | 10 | $9,694 |
| AstraZeneca | 5 | $5,327 |
| Mirati Therapeutics, Inc. | 5 | $2,324 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,908 |
| AbbVie | 3 | $1,828 |
| Jazz Pharmaceuticals Inc. | 1 | $1,590 |
| Novocure Inc. | 2 | $1,272 |
| Astrazeneca UK Limited | 3 | $158 |
| Johnson & Johnson | 1 | $134 |
| Genentech, Inc. | 1 | $93 |
| Merck | 4 | $48 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Telix Pharmaceuticals | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,382 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 52 | $925,340 |
| Lenalidomide | 62 | $858,227 |
| TagrissoOsimertinib Mesylate | 42 | $709,551 |
| PomalystPomalidomide | 21 | $390,404 |
| JakafiRuxolitinib Phosphate | 17 | $268,208 |
| AlunbrigBrigatinib | 12 | $218,218 |
| AlecensaAlectinib Hcl | 13 | $215,382 |
| VenclextaVenetoclax | 22 | $179,786 |
| CalquenceAcalabrutinib Maleate | 11 | $169,903 |
| DopteletAvatrombopag Maleate | 12 | $154,946 |
| XareltoRivaroxaban | 146 | $148,731 |
| ErleadaApalutamide | 14 | $139,693 |
| EliquisApixaban | 146 | $130,705 |
| Imatinib Mesylate | 25 | $12,181 |
| Enoxaparin Sodium | 74 | $6,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $5,327 | $879,45453 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $9,985 | $390,40421 claims |
| Johnson & JohnsonXarelto, Erleada | $134 | $288,425160 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $1,908 | $218,21812 claims |
| Genentech USA, Inc.Alecensa | $45,954 | $215,38213 claims |
| AbbVieVenclexta | $1,828 | $179,78622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Lone Tree
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.